Weight
Orforglipron
Metabolic
35
Amino acids
Molecular weight
Peptide
Type
Orforglipron (Foundayo) is a non-peptide, small-molecule GLP-1 receptor agonist — not a true peptide — developed by Eli Lilly and FDA-approved in April 2026 for chronic weight management in adults with obesity or overweight with weight-related comorbidities. It is taken once daily as an oral tablet with no food or water restrictions, distinguishing it from injectable GLP-1 therapies. Phase 3 trials demonstrated up to 11.2% mean body weight reduction at the 36 mg dose over 72 weeks, along with significant improvements in blood pressure, lipids, and glycemic control.
Top researched benefits
Overview of Orforglipron
Orforglipron selectively binds and activates the GLP-1 receptor (GLP-1R) at a transmembrane allosteric site, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via central hypothalamic GLP-1 pathways. It exhibits biased signaling — producing robust cAMP activation with low beta-arrestin recruitment — which reduces receptor internalization and may contribute to sustained efficacy relative to native GLP-1.
weight loss
- ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
- ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
- Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
- 91% achieved near-normal blood sugar levels versus 42% with placebo.
type 2 diabetes
- ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
- Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.
Typical Dose
Titration: 0.8 mg (month 1) → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg (month 6+); one step per month. Maximum maintenance dose is 17.2 mg once daily. Half-life range: 29–49 hours depending on dose.
Frequency
once daily
Cycle Duration
Monthly titration over 5–6 months to 17.2 mg maintenance; intended for ongoing long-term use
Storage
Oral tablet; no reconstitution required. Store at room temperature 20–25°C (68–77°F), excursions permitted to 15–30°C. Keep in original bottle and carton, protected from moisture and light. Research-grade powder: 0–4°C short-term, –20°C long-term.
Chemical Makeup
Key benefits
Produces up to 11.2% mean body weight reduction over 72 weeks at the 36 mg maintenance dose in Phase 3 obesity trials
Enables once-daily oral dosing with no food or water restrictions, removing adherence barriers associated with injectable or fasting-dependent GLP-1 therapies
Reduces HbA1c by up to 2.1 percentage points in adults with type 2 diabetes, supporting glycemic control independent of weight loss
Improves cardiometabolic markers including systolic blood pressure, LDL cholesterol, triglycerides, and waist circumference in obese patients
Community interest
This peptide is still gaining traction in the community.
GLP-1 Receptor Agonist | Obesity & Type 2 Diabetes
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoOrforglipron Molecular Information
View the scientifc details of Orforglipron.
35
Amino Acids
Orforglipron
Asn
Asn
Position 1
Pyl
Pyl
Position 2
Thr
Thr
Position 3
Ala
Ala
Position 4
Pro
Pro
Position 5
Pro
Pro
Position 6
Leu
Leu
Position 7
Ile
Ile
Position 8
Cys
Cys
Position 9
Ala
Ala
Position 10
Asx
Asx
Position 11
Leu
Leu
Position 12
Glu
Glu
Position 13
Ser
Ser
Position 14
Tyr
Tyr
Position 15
Asn
Asn
Position 16
Thr
Thr
Position 17
His
His
Position 18
Glu
Glu
Position 19
Thr
Thr
Position 20
Ile
Ile
Position 21
Cys
Cys
Position 22
Ser
Ser
Position 23
Met
Met
Position 24
Ala
Ala
Position 25
Leu
Leu
Position 26
Leu
Leu
Position 27
Met
Met
Position 28
Pyl
Pyl
Position 29
Leu
Leu
Position 30
Glu
Glu
Position 31
Cys
Cys
Position 32
Sec
Sec
Position 33
Leu
Leu
Position 34
Glu
Glu
Position 35
Molecular Weight
882.96DaChain Length
35Amino AcidsType
PeptideOrforglipron Protocols
Orforglipron (Foundayo) is taken as a once-daily oral tablet and is the only GLP-1 receptor agonist pill that can be administered at any time of day without food or water restrictions. Its small-molecule, non-peptide structure provides oral bioavailability of approximately 79% and a half-life of 29–49 hours, eliminating the need for injection or cold-chain storage.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Establish tolerability at the lowest dose (0.8 mg) before progressing through the titration schedule for chronic weight management | 0.8 | 1 day range | Oral tablet |
| Advance to 2.5 mg after at least 30 days on 0.8 mg to continue dose escalation toward the therapeutic range | 2.5 | 1 day range | Oral tablet |
| Reach the lowest dose shown to produce meaningful weight reduction; advance to 5.5 mg after at least 30 days on 2.5 mg | 5.5 | 1 day range | Oral tablet |
| Sustain clinically significant weight loss in patients who tolerate escalation to 9 mg without requiring maximum dosing | 9 | 1 day range | Oral tablet |
| Achieve greater weight reduction (target ≥10% body weight loss) in patients who tolerate and require escalation to 14.5 mg | 14.5 | 1 day range | Oral tablet |
| Maximize weight loss outcomes at the ceiling approved dose of 17.2 mg in adults with obesity or overweight with comorbidities who tolerate the full titration sequence | 17.2 | 1 day range | Oral tablet |
| Reduce HbA1c in adults with type 2 diabetes using a moderate maintenance dose within the approved titration range, based on Phase 3 trial data | 9 | 1 day range | Oral tablet |
| Achieve simultaneous body weight reduction and glycemic improvement in patients with type 2 diabetes and obesity at the maximum approved dose | 17.2 | 1 day range | Oral tablet |
| Reduce cardiometabolic risk markers (blood pressure, LDL, waist circumference) alongside weight loss in adults with obesity-related cardiovascular comorbidities at maximum tolerated dose | 17.2 | 1 day range | Oral tablet |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Swallow the tablet whole — do not crush, chew, or break it.
- Take once daily at any time of day, with or without food.
- Choose a consistent daily time and take orforglipron at that same time each day.
- If a dose is missed, take it on the same day as soon as remembered; if the next day has arrived, skip the missed dose and resume the regular schedule — do not double up.
- Store at room temperature (15–30°C) in the original packaging away from moisture and heat; no refrigeration required.
- Follow the monthly titration schedule: 0.8 mg for at least 4 weeks, then 2.5 mg, then 5.5 mg (lowest therapeutic dose), then increase further to 9 mg, 14.5 mg, or 17.2 mg (maximum) as tolerated.
Orforglipron Cycle
The Orforglipron Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 1-2
- Appetite reduction typically within 1-3 days; mild to moderate nausea common
- Week 2-4
- Gradual weight loss begins (0.5-2 lbs per week); improved blood sugar control
- Week 4-12
- Reduced food cravings; GI adverse effects generally diminish; metabolic markers improving
- Week 12-36
- Continued progressive weight loss without plateau
- Week 0-0
- Long-term therapy well-tolerated; sustained benefits at 72 weeks
Dosing tools
Orforglipron Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The dose you want to inject per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
Orforglipron
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Orforglipron vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Reference Guide
Dosing Cycle
- Peptide
- Orforglipron
- Dosing
- Titration: 0.8 mg (month 1) → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg (month 6+); one step per month. Maximum maintenance dose is 17.2 mg once daily. Half-life range: 29–49 hours depending on dose.
- Dosing Frequency
- once daily
- Cycle Duration
- Monthly titration over 5–6 months to 17.2 mg maintenance; intended for ongoing long-term use
- Storage
- Oral tablet; no reconstitution required. Store at room temperature 20–25°C (68–77°F), excursions permitted to 15–30°C. Keep in original bottle and carton, protected from moisture and light. Research-grade powder: 0–4°C short-term, –20°C long-term.
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of Orforglipron interactions with other common peptides and substances.
Healing
bpc
Longevity
BPC-157
COMPATIBLE
No known interactions; may support gut health and potentially mitigate GI adverse effects.
Weight
GLP-1
Metabolic
GLP-1
AVOID
Both are GLP-1 agonists; combining increases severe hypoglycemia and excessive GI adverse effects.
Side effects
Avoid: Do not take Orforglipron with GLP-1.
Contraindications
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy and breastfeeding
Stop signs
Severe or persistent abdominal pain radiating to back (potential pancreatitis)
Neck lumps, hoarseness, difficulty swallowing, or neck swelling
Severe nausea/vomiting preventing adequate nutrition or hydration
Signs of severe hypoglycemia (confusion, sweating, rapid heartbeat)
Suicidal thoughts, severe depression, or significant mood changes
Vision changes or persistent eye pain
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
OrforglipronResearch References
Orforglipron is a fda approved compound
Orforglipron
Orforglipron is a fda approved compound
ATTAIN-1 Phase 3 Trial (Obesity)
3,127 adults; 72 weeks. 36mg dose achieved 12.4% weight loss (27.3 lbs) versus 2.1% placebo. First oral small-molecule GLP-1 completing Phase 3.
2025
ATTAIN-2 Phase 3 Trial (Obesity + Type 2 Diabetes)
1,613 adults; 72 weeks. 36mg dose achieved 10.5% weight loss with 72.8% achieving ≥5% weight loss.
2025
ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes)
559 adults; 40 weeks. All doses significantly reduced HbA1c by 1.3-1.6%; 76.2% achieved HbA1c <7%.
2025
Phase 2 Obesity Study
272 adults; 36 weeks. Achieved up to 14.7% mean weight reduction at 36 weeks with 45mg dose.
2023
Calculate peptide dosages
Learning how to calculate a peptide dose? Use our beginner-friendly peptide dosage, blend, and accumulation calculators. Enter vial size, reconstitution volume, and target dose to get exact draw volumes instantly. No guesswork, just clear guidance that helps prevent common mistakes.
